TCD 51073Alternative Names: TCD-51073
Latest Information Update: 17 Aug 2016
At a glance
- Originator Terumo
- Class Cardiovascular therapies; Heart failure therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure
Most Recent Events
- 04 Feb 2013 Phase-II clinical trials in Heart failure (due to chronic ischaemic heart disease) in Japan (unspecified route)